Editorial Commentary
Perioperative chemo immunotherapy in non-small-cell lung cancer: what can we learn from the long-term results of NADIM?
Translational Lung Cancer Research
2025;
14
(11)
:4704-4710
.
(30 November 2025)
Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?
Translational Lung Cancer Research
2025;
14
(11)
:4711-4714
.
(30 November 2025)
T cell receptor (TCR)-based therapy in advanced non-small cell lung cancer: a new hope?
Translational Lung Cancer Research
2025;
14
(11)
:4715-4718
.
(30 November 2025)
Original Article
Defining the surgical curative time window: identifying patients with an absence of recurrence for 5 years following surgical resection of stage I invasive non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(11)
:4719-4732
.
(30 November 2025)
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy
Translational Lung Cancer Research
2025;
14
(11)
:4733-4745
.
(30 November 2025)
Integrative modeling of longitudinal cell-free DNA and tumor volume dynamics: a multimodal quantitative prognostic framework
Translational Lung Cancer Research
2025;
14
(11)
:4746-4755
.
(30 November 2025)
Efficacy and safety of immune checkpoint inhibitors in advanced non-small cell lung cancer with idiopathic interstitial pneumonia or interstitial lung abnormalities: NJLCG2301
Translational Lung Cancer Research
2025;
14
(11)
:4756-4767
.
(30 November 2025)
Deep structural lipidomic profiling reveals C=C positional isomers as potential biomarkers in lung adenocarcinoma tissue
Translational Lung Cancer Research
2025;
14
(11)
:4768-4783
.
(30 November 2025)
Subtype-specific RNA sequencing using micro-dissection revealed extracellular matrix alterations as key factors in lung adenocarcinoma invasion
Translational Lung Cancer Research
2025;
14
(11)
:4784-4795
.
(30 November 2025)
Treatment interruption during neoadjuvant immuno-chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
Translational Lung Cancer Research
2025;
14
(11)
:4796-4810
.
(30 November 2025)
Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data
Translational Lung Cancer Research
2025;
14
(11)
:4811-4823
.
(30 November 2025)
Prognostic impact of ALK rearrangement in surgically treated stage I lung adenocarcinoma: a retrospective cohort study
Translational Lung Cancer Research
2025;
14
(11)
:4824-4837
.
(30 November 2025)
High GLUT1 protein expression is associated with unfavorable tumor features and poor prognosis in non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(11)
:4838-4848
.
(30 November 2025)
Comparative effectiveness and safety of systemic therapies for treatment-naïve, PD-L1 expression <1% advanced NSCLC: a systematic review and network meta-analysis
Translational Lung Cancer Research
2025;
14
(11)
:4849-4867
.
(30 November 2025)
Establishment and characterization of an orthotopic implanted lung cancer model to mimic human tumor structure, microenvironment, and metastatic spread
Translational Lung Cancer Research
2025;
14
(11)
:4868-4895
.
(30 November 2025)
Is seeing believing?—signal differentiation in a preclinical transbronchial imaging study implementing a composite optical fiber bronchoscope to detect a folate receptor-targeted near-infrared fluorophore
Translational Lung Cancer Research
2025;
14
(11)
:4896-4905
.
(30 November 2025)
Whole genome characterization of patient-derived lung cancer organoids
Translational Lung Cancer Research
2025;
14
(11)
:4906-4922
.
(30 November 2025)
PD-L1 expression in primary lung tumor as a superior predictive biomarker to metastatic lymph nodes for first-line immunochemotherapy in advanced KRAS-mutant non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(11)
:4923-4941
.
(30 November 2025)
Stage- and smoking-associated microRNA expression in lung adenocarcinoma
Translational Lung Cancer Research
2025;
14
(11)
:4942-4961
.
(30 November 2025)
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(11)
:4962-4972
.
(30 November 2025)
Unveiling the clinical impact of plasma-only mutations in non-small cell lung cancer: a Korean multicenter experience
Translational Lung Cancer Research
2025;
14
(11)
:4973-4982
.
(30 November 2025)
A public data-based molecular classification of small cell lung cancer by neuroactive signaling networks unveils distinct microenvironment landscapes and immunotherapy-related prognostic biomarkers
Translational Lung Cancer Research
2025;
14
(11)
:4983-4999
.
(30 November 2025)
Immune checkpoint inhibitors have limited efficacy in SMARCA4-deficient non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(11)
:5000-5016
.
(30 November 2025)
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study
Translational Lung Cancer Research
2025;
14
(11)
:5017-5030
.
(30 November 2025)
c-MET expression and immune landscape in locally advanced patients with non-small cell lung cancer undergoing radiochemotherapy and consolidative immunotherapy
Translational Lung Cancer Research
2025;
14
(11)
:5031-5043
.
(30 November 2025)
Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study
Translational Lung Cancer Research
2025;
14
(11)
:5044-5058
.
(30 November 2025)
Development and validation of a multivariable prognostic model incorporating black-blood magnetic resonance imaging-based meningeal lymphatic remodeling to predict therapy response in non-small cell lung cancer brain metastases
Translational Lung Cancer Research
2025;
14
(11)
:5059-5073
.
(30 November 2025)
Brief Report
Circulating stem-like exhausted CD8 T cells point to better outcomes in lung cancer: a brief report
Translational Lung Cancer Research
2025;
14
(11)
:5074-5081
.
(30 November 2025)
Review Article
Redefining treatment interval in lung cancer surgery in the era of prehabilitation: a systematic review
Translational Lung Cancer Research
2025;
14
(11)
:5082-5098
.
(30 November 2025)
Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment
Translational Lung Cancer Research
2025;
14
(11)
:5099-5117
.
(30 November 2025)
A narrative review of pathologic response in non-small cell lung cancer: challenges, implications, and future directions
Translational Lung Cancer Research
2025;
14
(11)
:5118-5136
.
(30 November 2025)
The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review
Translational Lung Cancer Research
2025;
14
(11)
:5137-5158
.
(30 November 2025)
Robotic-assisted and electromagnetic navigation bronchoscopy for multi-focal lung cancers: a narrative review
Translational Lung Cancer Research
2025;
14
(11)
:5159-5180
.
(30 November 2025)
Decoding the enigma of multiple primary lung cancers: from mechanism to bedside—a narrative review
Translational Lung Cancer Research
2025;
14
(11)
:5181-5197
.
(30 November 2025)
Letter to the Editor
A new hope for aggressive thoracic cancers: foundational efficacy of frontline immunotherapy in SMARCA4-deficient tumors
Translational Lung Cancer Research
2025;
14
(11)
:5198-5199
.
(30 November 2025)
Retrospective evaluation of anti-angiogenic and immune checkpoint inhibitor combination therapy in SMARCA4-deficient thoracic tumors: efficacy, safety, and biomarker considerations
Translational Lung Cancer Research
2025;
14
(11)
:5200-5202
.
(30 November 2025)
